Matt brings over 18 years of experience with a proven track record of driving EBITDA growth, operational scale, and strategic value creation across private equity-backed, public, and high-growth life sciences organizations. He is recognized for bridging the gap between finance and operations, translating financial strategy into operational discipline in environments ranging from VC-backed startups to PE-backed enterprises.
Previously, Matt led global finance and transformation initiatives at Abzena and held senior finance leadership roles at Ligand Pharmaceuticals and Enovis (Blackstone PE-backed), where he managed the execution of a two-year strategic operational plan across 10 initiatives, spanning sales, product profitability, outsourcing, reimbursement, receivables and payables, liquidity, and organizational effectiveness, leading to successful M&A activity.
Matt is the partner you want when financial discipline and operational execution need to move together. He brings a rare ability to see both the numbers and the operating system behind them, and to build the structures that make improvement stick.
Matt is a biopharma program and operations leader with 19 years of experience leading programs from diligence and early discovery through regulatory approval and commercialization, across cell therapies, biologics, and other advanced modalities. He is known for making the complex actionable: rapidly synthesizing scientific and business information, identifying what truly matters, and building integrated development plans that allow for actionable execution.
Most recently, Matt served as VP of Portfolio and Program Management at a VC-backed Series A cell therapy company, where he advanced the lead program from initial discovery through Phase 1 submission. Beyond program execution, he played a defining role in company operations and culture: establishing the standards of excellence and high-character leadership that shaped how the team operated at every level.
Earlier in his career, Matt spent nine years at Amgen, including five years in Operations Strategic Planning, where he supported business development and network strategies.
Matt is the partner you want when a program is complex, the stakes are high, and the path forward isn't yet clear. He brings deep technical fluency in CMC and cell therapy development alongside the program management discipline to drive cross-functional teams from early discovery through regulatory submission.
What distinguishes Matt is his ability to operate across levels: equally effective strategizing with senior leadership, leading scientific strategy with R&D, and building the operational infrastructure a growing company needs. Clients engage him not just to run programs, but to raise the standard of how the organization operates.
Aaron brings 15+ years of experience building and scaling life sciences companies across strategy, operations, and finance. He has held senior operating roles across the full company lifecycle, from early-stage startup to commercial-stage biotech, and is recognized for distilling complex organizational challenges into clear, prioritized strategies that deliver results.
Prior to that, Aaron spent several years at Atara Biotherapeutics in a series of expanding roles. He served as the initial commercial launch lead for Ebvallo, the world's first approved allogeneic cell therapy, then served as Chief of Staff for the Operations group, overseeing quality reorganization and PAI readiness. He went on to manage four pipeline programs and led the divestiture of Atara's cell therapy manufacturing facility.
Earlier in his career, Aaron spent several years at ZS Associates working with 20+ clients across biologics, small molecule, oncology, and CDMOs. Before that, he held roles in corporate strategy at Baxter and started in private equity and M&A.
Aaron has worked with companies of every size and founder type, across multiple therapeutic areas and modalities. That breadth, combined with operating experience at every stage of the product lifecycle, means he gets to the real problem quickly and helps teams figure out what actually matters. He is equally comfortable in a strategy conversation and a hands-on execution role, and tends to be most useful in moments where the path forward isn't obvious and someone needs to connect the dots across functions.
Josh has more than 18 years of experience leading global supply chain and manufacturing operations in the biopharmaceutical and cell therapy sectors. He is recognized for building strong alliances with CDMOs and strategic suppliers, designing processes that deliver measurable impact, and leading high-performing teams through complex operational environments.
Earlier in his career, Josh managed regional and global supply chain operations at Amgen and Atara Biotherapeutics, enhancing delivery performance and mitigating risk across complex networks. He most recently supported a stealth-mode cell therapy company, where he managed strategic partnerships, led tech transfer activities, and directed strategic sourcing and procurement to ensure seamless delivery of critical materials and process optimization globally.
Josh is the partner you want when supply chain complexity is the bottleneck, whether that's a tech transfer that needs to move faster, a CDMO relationship that needs restructuring, or a manufacturing network that needs to scale without breaking. He brings 18+ years of real operating experience to every engagement.